Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Travere Therapeutics ( (TVTX) ) just unveiled an update.
On May 15, 2025, Travere Therapeutics held its Annual Meeting where stockholders voted on several proposals. The company elected ten directors to serve until the 2026 Annual Meeting, approved an amendment to increase shares under the 2018 Equity Incentive Plan, approved executive compensation, and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. These decisions reflect the company’s ongoing governance and strategic planning efforts.
The most recent analyst rating on (TVTX) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Travere Therapeutics stock, see the TVTX Stock Forecast page.
Spark’s Take on TVTX Stock
According to Spark, TipRanks’ AI Analyst, TVTX is a Neutral.
Travere Therapeutics presents a mixed outlook with notable revenue growth driven by FILSPARI sales and strategic progress highlighted in the earnings call and corporate event. However, persistent financial challenges, high leverage, and unattractive valuation weigh down the score. The positive technical momentum provides some optimism, but overall, the stock score reflects a cautious stance given the financial instability and near-term headwinds.
To see Spark’s full report on TVTX stock, click here.
More about Travere Therapeutics
Average Trading Volume: 1,734,891
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.87B
For detailed information about TVTX stock, go to TipRanks’ Stock Analysis page.